Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eytan M. Stein, Courtney Denton Dinardo, Daniel Aaron Pollyea, Amir Tahmasb Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Ian Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Anthony Selwyn Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Robert D. Knight, Samuel V. Agresta, Stéphane de Botton, Martin S. Tallman
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Colorado Cancer Center, Harvard University, Massachusetts General Hospital, NewYork–Presbyterian Hospital, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Dana-Farber Cancer Institute, Sarah Cannon, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, Cleveland Clinic, University of Miami, Sylvester Comprehensive Cancer Center, Stanford Medicine, Stanford University, Celgene (United States), Agios Pharmaceuticals (United States), Institut Gustave Roussy
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890900426